Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.
Peyvandi F, Berger K, Seitz R, Hilger A, Hecquet ML, Wierer M, Buchheit KH, O'Mahony B, Bok A, Makris M, Mansmann U, Schramm W, Mannucci PM. Peyvandi F, et al. Haematologica. 2020 Aug;105(8):2038-2043. doi: 10.3324/haematol.2019.242735. Epub 2020 May 28. Haematologica. 2020. PMID: 32467138 Free PMC article.
Economics of prophylactic treatment.
Schramm W, Berger K. Schramm W, et al. Haemophilia. 2003 May;9 Suppl 1:111-5; dicussion 116. doi: 10.1046/j.1365-2516.9.s1.14.x. Haemophilia. 2003. PMID: 12709046 Review.
Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.
Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, van Hout BA, Willan AR, Feldman BM. Nicholson A, et al. Haemophilia. 2008 Jan;14(1):127-32. doi: 10.1111/j.1365-2516.2007.01562.x. Epub 2007 Nov 13. Haemophilia. 2008. PMID: 18005148
Haemophilia prophylaxis: how can we justify the costs?
Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan AR, Schramm W. Feldman BM, et al. Haemophilia. 2012 Sep;18(5):680-4. doi: 10.1111/j.1365-2516.2012.02790.x. Epub 2012 Apr 17. Haemophilia. 2012. PMID: 22507524 Review.
Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective.
Fischer K, Poonnoose P, Dunn AL, Babyn P, Manco-Johnson MJ, David JA, van der Net J, Feldman B, Berger K, Carcao M, de Kleijn P, Silva M, Hilliard P, Doria A, Srivastava A, Blanchette V; participants of the International Symposium on Outcome Measures in Hemophilic Arthropathy. Fischer K, et al. Haemophilia. 2017 Jan;23(1):11-24. doi: 10.1111/hae.13088. Epub 2016 Sep 15. Haemophilia. 2017. PMID: 27633342 Review.
Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B, Berger K, Berntorp E, Giangrande P, van den Berg M, Schramm W, Siebert U; European Haemophilia Economic Study Group. Lippert B, et al. Blood Coagul Fibrinolysis. 2005 Oct;16(7):477-85. doi: 10.1097/01.mbc.0000178830.39526.ff. Blood Coagul Fibrinolysis. 2005. PMID: 16175006
Influencing blood usage in Germany: what is optimal use?
Schramm W, Berger K. Schramm W, et al. Transfusion. 2007 Aug;47(2 Suppl):152S-154S; discussion 155S-156S. doi: 10.1111/j.1537-2995.2007.01374.x. Transfusion. 2007. PMID: 17651341 No abstract available.
Haemophilia care in Europe: the ESCHQoL study.
Schramm W, Gringeri A, Ljung R, Berger K, Crispin A, Bullinger M, Giangrande PL, Von Mackensen S, Mantovani LG, Nemes L, Serban M; ESCHQOL Study Group. Schramm W, et al. Haemophilia. 2012 Sep;18(5):729-37. doi: 10.1111/j.1365-2516.2012.02847.x. Epub 2012 May 29. Haemophilia. 2012. PMID: 22639833
54 results